Healthcare / BiotechnologyWarsaw
$1.80
-0.06 (-3.02%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-10.8M · quality 67.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$22M
P/E
N/A
•EV/EBITDA
N/A
•ROE
69.4%
↑Gross Margin
N/A
•Debt/Equity
-1.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-9.8M · FCF $-6.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | — | $662000.00 |
| Net Income | $-9.8M | $-9.8M | $-19.4M | $-35.7M | $-25.6M |
| EBITDA | $-5.5M | $-5.5M | $-11.6M | $-9.1M | $-22.8M |
| EPS | -1.99 | -1.99 | -2.38 | -4.76 | -4.84 |
| Gross Margin | — | — | — | — | -816.8% |
| Operating Margin | — | — | — | — | -3728.2% |
| Net Margin | — | — | — | — | -3867.5% |
| Balance Sheet | |||||
| Debt/Equity | -1.13 | -1.13 | -1.07 | 6.83 | 0.16 |
| Current Ratio | 0.25 | 0.25 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.2M | $-6.2M | $-10.8M | $-23.4M | $-23.1M |
| Returns | |||||
| ROE | 69.4% | 69.4% | 148.2% | -1885.6% | -139.9% |
| Valuation | |||||
| P/B | — | — | — | 55.49 | 7.29 |
| Growth & Yield | |||||
| EPS Growth | 16.2% | 16.2% | 50.1% | 1.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-75.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.38 → -1.99
Residual
-75.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.